PT - JOURNAL ARTICLE AU - Nomura, Yushi AU - Sawahata, Michiru AU - Nakamura, Yosikazu AU - Kurihara, Momoko AU - Koike, Ryousuke AU - Katsube, Otohiro AU - Hagiwara, Koichi AU - Niho, Seiji AU - Masuda, Norihiro AU - Tanaka, Takaaki AU - Sugiyama, Kumiya TI - Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine AID - 10.1101/2021.08.06.21261590 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.06.21261590 4099 - http://medrxiv.org/content/early/2021/08/07/2021.08.06.21261590.short 4100 - http://medrxiv.org/content/early/2021/08/07/2021.08.06.21261590.full AB - Objective We aimed to determine antibody (Ab) titres 3 months after the second dose of the BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables predicting these titres in Japan.Methods We enrolled 378 healthcare workers (255 women, 123 men) whose blood samples were collected 91±15 days after the second of two inoculations of the BNT162b2 COVID-19 mRNA vaccine (Pfizer/BioNTech) given 3 weeks apart. Medical histories and demographic characteristics were recorded using a structured self-reported questionnaire. The relationships between Ab titres and these factors were analysed.Results Median age (interquartile range [IQR]) of the participants was 44 (32-54) years. Median Ab titre (IQR) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigen was 764 (423-1140) U/mL. Older participants had significantly lower Ab titres; median (IQR) Ab titres were 942 (675-1390) and 1095 (741-1613) U/mL in men and women in their 20s, respectively, but 490 (297-571) and 519 (285-761) U/mL in men and women in their 60s-70s, respectively. In the age-adjusted analysis, the only risk factors for lower Ab titres were male sex and smoking. However, the sex difference may have arisen from the sex difference in smoking rate. Moreover, Ab titres were significantly lower in current smokers than in ex-smokers.Conclusion The most important factors associated with low Ab titres were age and smoking habit. In particular, current smoking status caused lower Ab titres, and smoking cessation before vaccination may improve the individual efficacy of the BNT162b2 vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundings.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of National Hospital Organization Utsunomiya National Hospital (No. 03-01, April 19, 2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.